File Download
There are no files associated with this item.
Supplementary
-
Citations:
- Appears in Collections:
Conference Paper: Surgical options in hereditary breast cancer
Title | Surgical options in hereditary breast cancer |
---|---|
Authors | |
Issue Date | 2022 |
Publisher | Korean Breast Cancer Society. |
Citation | Global Breast Cancer Conference (GBCC) 2022, Virtual Conference, Seoul, Korea, 28-30 April 2022 How to Cite? |
Abstract | Women who have inherited mutations in breast cancer susceptibility genes mutations such as BRCA1
and BRCA2 have substantially elevated risks of breast and ovarian cancer. With the emergence of next
generation sequencing, more breast cancer susceptibility genes have been identified resulting in
complexity in genetic counselling and decision making for management options more complex.
Mutation carriers have various options, including extensive and regular surveillance, chemoprevention
and risk-reducing surgery. Prophylactic surgery (bilateral mastectomy, bilateral salpingo-oophorectomy
or a combination of both procedures) has proved to be the most effective risk-reducing strategy for
breast cancer and ovarian cancer, but there are no randomised controlled trials able to demonstrate the
potential benefits or harms of prophylactic surgery. Although it is not uncommon to perform
mastectomy when a mutation carrier is encountered, breast conservation is not completely
contraindicated. Based on the current knowledge, it is also reasonable to recommend prophylactic
oophorectomy for BRCA1 or BRCA2 mutation carriers when childbearing is completed in order to
reduce the risk of developing breast and ovarian cancer. In addition, women should be offered the
options of intensive breast surveillance, chemoprevention apart from bilateral prophylactic mastectomy.
The selection of the most appropriate surgical options with or without risk-reducing strategy however is
not simple. The impact of risk-reducing strategies on cancer risk, survival, and overall quality of life are
the key criteria considered for decision-making. Various other factors should be taken into
consideration when evaluating individual mutation carriers’ individual situation, namely woman’s age,
morbidity, type of mutation, and individual preferences and expectations. Strategies and existing
guidelines will be reviewed and discussed. |
Description | Oral Presentation - HBOC Session: Hereditary Breast/Ovarian Cancer Syndrome |
Persistent Identifier | http://hdl.handle.net/10722/313459 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kwong, A | - |
dc.date.accessioned | 2022-06-17T06:46:43Z | - |
dc.date.available | 2022-06-17T06:46:43Z | - |
dc.date.issued | 2022 | - |
dc.identifier.citation | Global Breast Cancer Conference (GBCC) 2022, Virtual Conference, Seoul, Korea, 28-30 April 2022 | - |
dc.identifier.uri | http://hdl.handle.net/10722/313459 | - |
dc.description | Oral Presentation - HBOC Session: Hereditary Breast/Ovarian Cancer Syndrome | - |
dc.description.abstract | Women who have inherited mutations in breast cancer susceptibility genes mutations such as BRCA1 and BRCA2 have substantially elevated risks of breast and ovarian cancer. With the emergence of next generation sequencing, more breast cancer susceptibility genes have been identified resulting in complexity in genetic counselling and decision making for management options more complex. Mutation carriers have various options, including extensive and regular surveillance, chemoprevention and risk-reducing surgery. Prophylactic surgery (bilateral mastectomy, bilateral salpingo-oophorectomy or a combination of both procedures) has proved to be the most effective risk-reducing strategy for breast cancer and ovarian cancer, but there are no randomised controlled trials able to demonstrate the potential benefits or harms of prophylactic surgery. Although it is not uncommon to perform mastectomy when a mutation carrier is encountered, breast conservation is not completely contraindicated. Based on the current knowledge, it is also reasonable to recommend prophylactic oophorectomy for BRCA1 or BRCA2 mutation carriers when childbearing is completed in order to reduce the risk of developing breast and ovarian cancer. In addition, women should be offered the options of intensive breast surveillance, chemoprevention apart from bilateral prophylactic mastectomy. The selection of the most appropriate surgical options with or without risk-reducing strategy however is not simple. The impact of risk-reducing strategies on cancer risk, survival, and overall quality of life are the key criteria considered for decision-making. Various other factors should be taken into consideration when evaluating individual mutation carriers’ individual situation, namely woman’s age, morbidity, type of mutation, and individual preferences and expectations. Strategies and existing guidelines will be reviewed and discussed. | - |
dc.language | eng | - |
dc.publisher | Korean Breast Cancer Society. | - |
dc.relation.ispartof | Global Breast Cancer Conference (GBCC) 2022 | - |
dc.title | Surgical options in hereditary breast cancer | - |
dc.type | Conference_Paper | - |
dc.identifier.email | Kwong, A: avakwong@hku.hk | - |
dc.identifier.authority | Kwong, A=rp01734 | - |
dc.identifier.hkuros | 333530 | - |
dc.publisher.place | Korea | - |